These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 10500563)

  • 1. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin.
    Gómez G; Alvarez ML; Errasti P; Lavilla FJ; García N; Ballester B; García I; Purroy A
    Transplant Proc; 1999 Sep; 31(6):2250-1. PubMed ID: 10500563
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical features of acute reversible tacrolimus (FK 506) nephrotoxicity in kidney transplant recipients.
    Katari SR; Magnone M; Shapiro R; Jordan M; Scantlebury V; Vivas C; Gritsch A; McCauley J; Starzl T; Demetris AJ; Randhawa PS
    Clin Transplant; 1997 Jun; 11(3):237-42. PubMed ID: 9193849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of acute tacrolimus nephrotoxicity in renal allografts.
    Shimizu T; Tanabe K; Tokumoto T; Ishikawa N; Shimmura H; Oshima T; Toma H; Yamaguchi Y
    Transplant Proc; 2000 Nov; 32(7):1914-6. PubMed ID: 11119998
    [No Abstract]   [Full Text] [Related]  

  • 4. Tacrolimus nephrotoxicity after renal transplantation.
    Katari SR; Magnone M; Shapiro R; Jordan M; Scantlebury V; Vivas C; Gritsch HA; McCauley J; Starzl T; Demetris AJ; Randhawa PS
    Transplant Proc; 1997; 29(1-2):311. PubMed ID: 9123014
    [No Abstract]   [Full Text] [Related]  

  • 5. Improvement of nephrotoxicity, hypertension, and lipid metabolism after conversion of kidney transplant recipients from cyclosporine to tacrolimus.
    Friemann S; Feuring E; Padberg W; Ernst W
    Transplant Proc; 1998 Jun; 30(4):1240-2. PubMed ID: 9636504
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report.
    Jurewicz WA
    Transplant Proc; 1999 Nov; 31(7A):64S-66S. PubMed ID: 10576048
    [No Abstract]   [Full Text] [Related]  

  • 7. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression.
    Schmidt RJ; Venkat KK; Dumler F
    Transplant Proc; 1991 Dec; 23(6):3156-7. PubMed ID: 1721390
    [No Abstract]   [Full Text] [Related]  

  • 8. Beneficial effect of multiple drug therapy including tacrolimus in clinical renal transplantation.
    Okamoto M; Yoshimura N; Nakai I; Nakajima H; Ushigome H; Sakaguchi K; Ohmori Y; Yoshimura R; Sugioka N; Oka T
    Transplant Proc; 2000 Nov; 32(7):1716-7. PubMed ID: 11119905
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination therapy of tacrolimus (FK506) with azathioprine and steroids in renal transplant recipients.
    Yoshimura N; Oka T; Ohmori Y; Yasumura T; Nakai I; Hamashima T; Nakajima H; Okamoto M; Nakamura K; Mizuta N
    Transplant Proc; 1998 Feb; 30(1):33-5. PubMed ID: 9474949
    [No Abstract]   [Full Text] [Related]  

  • 10. Vascular microthrombosis in renal transplant recipients treated with tacrolimus.
    Antoine C; Thakur S; Daugas E; Fraoui R; Boudjeltia S; Julia P; Nochy D; Glotz D
    Transplant Proc; 1998 Sep; 30(6):2813-4. PubMed ID: 9745577
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization.
    Nakache R; Weinbroum A; Merhav H; Katz P; Kaplan E
    Transplant Proc; 2001 May; 33(3):2294-5. PubMed ID: 11377533
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical study of FK 506 in renal transplant recipients.
    Youhua Z; Zhinlian M; Liming W
    Transplant Proc; 2000 Nov; 32(7):1704. PubMed ID: 11119900
    [No Abstract]   [Full Text] [Related]  

  • 13. Histopathologic findings in routine biopsies of renal transplant allografts.
    Toki K; Kyo M; Takahara S; Hatori M; Morozumi K; Ichimaru N; Wang JD; Ding XQ; Miyamoto M; Oka K; Kyakuno M; Kojima Y; Kokado Y; Okuyama A
    Transplant Proc; 1999 Sep; 31(6):2655-8. PubMed ID: 10500759
    [No Abstract]   [Full Text] [Related]  

  • 14. Tubular damage and impairment of renal function in transplanted kidneys.
    Donadio C; Puccini R; Lucchesi A; Giordani R; Rizzo G
    Transplant Proc; 1998 Aug; 30(5):2036-7. PubMed ID: 9723381
    [No Abstract]   [Full Text] [Related]  

  • 15. Is cyclosporine toxic to the transplanted kidney with acute tubular necrosis?
    Ritz M; Pascoe MD; Pontin AR; Kahn D
    Transplant Proc; 1998 Jun; 30(4):1204. PubMed ID: 9636488
    [No Abstract]   [Full Text] [Related]  

  • 16. Simple tacrolimus-based immunosuppressive regimens following renal transplantation: a large multicenter comparison between double and triple therapy.
    Pascual J; Ortuño J;
    Transplant Proc; 2002 Feb; 34(1):89-91. PubMed ID: 11959198
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion from cyclosporine to tacrolimus in kidney, kidney/pancreas, and pancreas alone transplant recipients: the Memphis experience.
    Alloway RR; Russell WC; Gaber LW; Amiri MH; Vera SR; Gaber AO
    Transplant Proc; 1996 Apr; 28(2):995-7. PubMed ID: 8623494
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of tolerability, safety, and efficacy of cyclosporine microemulsion in renal transplant recipients.
    Gracida C; Melchor JL; Miranda ME; Bartolano C
    Transplant Proc; 1996 Aug; 28(4):2171-3. PubMed ID: 8769191
    [No Abstract]   [Full Text] [Related]  

  • 19. Conversion from cyclosporine to tacrolimus in renal allograft recipients with delayed graft function from severe acute tubular necrosis.
    Jang HJ; Kim SC; Han DJ
    Transplant Proc; 2000 Nov; 32(7):1714-5. PubMed ID: 11119904
    [No Abstract]   [Full Text] [Related]  

  • 20. Clinical safety and tolerability of microemulsion cyclosporine in stable renal transplant patients.
    Gracida C; Melchor JL
    Transplant Proc; 1996 Dec; 28(6):3379. PubMed ID: 8962318
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.